GRN-1201

BrightPath Biotherapeutics · Phase 1 active Biologic

At a glance

Generic name	GRN-1201
Sponsor	BrightPath Biotherapeutics
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC (PHASE2)
Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GRN-1201 CI brief — competitive landscape report
GRN-1201 updates RSS · CI watch RSS
BrightPath Biotherapeutics portfolio CI